Attention Deficit Hyperactivity Disorder (ADHD) News and Research

RSS

Attention Deficit Hyperactivity Disorder (ADHD)

Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral).

Functional disconnection between brain regions in ADHD children

Two brain areas fail to connect when children with attention deficit hyperactivity disorder attempt a task that measures attention, according to researchers at the UC Davis Center for Mind and Brain and M.I.N.D. Institute.

12 Jan 2010

Positive results from KemPharm's KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm’s proprietary Ligand Activated Therapy (LAT) prodrug approach.

12 Jan 2010

Targacept signs collaboration and license agreement with AstraZeneca

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that its collaboration and license agreement with AstraZeneca for the global development and commercialization of TC-5214 for major depressive disorder (MDD) has become effective as a result of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

11 Jan 2010

EON Reality supports BBU with immersive EON Icube environment for virtual reality therapy project

EON Reality, the world's leading interactive 3D software provider, supports the Babes-Bolyai University (BBU), in Cluj-Napoca, Romania with an immersive EON Icube environment for a virtual reality therapy project.

9 Jan 2010

Center for Attention Deficit and Learning Disorders adds HEG to its list of treatment options

The Center for Attention Deficit and Learning Disorders announces today that it has added Hemoencephalography (HEG) to its list of treatment options for patients with ADD/ADHD, learning disabilities, mood disorders and other conditions.

8 Jan 2010

New system that reduces ADHD symptoms in children to be rolled out across the UK

A new thought-operated computer system which can reduce the symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in children will be rolled out across the UK this month.

7 Jan 2010

Ben-Gurion University researcher defines integrated interpretation of ASD

A researcher from Ben-Gurion University of the Negev has defined a new, integrated interpretation of Autism Spectrum Disorders (ASD), which makes it easier to understand both the commonalities and differences between ASD and other conditions.

5 Jan 2010

Ligand Pharmaceuticals acquires Neurogen

Ligand Pharmaceuticals Incorporated announced today that it has completed the acquisition of Neurogen Corporation, following approval of the transaction by Neurogen stockholders earlier today. As a result, Ligand gains a fully funded partnership with Merck & Co., additional pipeline assets, drug discovery resources and additional cash balances.

23 Dec 2009

ADHD Support Twitter page from Shire

Shire plc, the global specialty biopharmaceutical company, announced the launch of its newest online Attention-Deficit/Hyperactivity Disorder (ADHD) resource, the ADHD Support Twitter(TM) page (http://twitter.com/adhdsupport), derived from the Shire award-winning online educational resource, ADHDSupport.com.

22 Dec 2009

Diet rich in omega-3 fatty acids linked to improved nervous-system function

The omega-3 essential fatty acids commonly found in fatty fish and algae help animals avoid sensory overload, according to research published by the American Psychological Association.

17 Dec 2009

Survey provides comprehensive look at prevalence of common mental disorders

Only about half of American children and teenagers who have certain mental disorders receive professional services, according to a nationally representative survey funded in part by the National Institute of Mental Health (NIMH). The survey also provides a comprehensive look at the prevalence of common mental disorders.

14 Dec 2009

UnitedHealth Group invests $5.4M in The Help Group’s tax-exempt revenue bonds

The Help Group received $5,395,000 in capital that will support development of its newest campus serving Los Angeles-area children, adolescents and young adults with autism spectrum disorders.

10 Dec 2009

Comprehensive report details the prevalence, implications, costs of caregiving and demographics of caregivers

Caregiving is still mostly a woman's job and many women are putting their career and financial futures on hold as they juggle part-time caregiving and full-time job requirements.

9 Dec 2009

Increased sense of separation in this holiday season's most harmful gifts

A couple years ago, lead paint in toys manufactured in China sent parents searching frantically for gifts made in the USA. This fall, news of Baby Einstein refunds suggested that even so-called educational toys are suspect. Renowned parenting expert Dr. Jeffrey Fine, Ph.D., says that such videos are actually harmful to developing brains, retarding language development and shortening attention spans. Moreover, there is an increased sense of separation, which is the defining trait of each of this holiday season's most harmful gifts.

7 Dec 2009

Native Remedies selects TransMedia Group as its PR firm

With more than 500,000 customers worldwide, the market leader in all-natural herbal and homeopathic remedies for people and their pets, Native Remedies, has engaged TransMedia Group as their PR firm of record. The company's two brands, Native Remedies (www.nativeremedies.com) and PetAlive (www.PetAlive.com), provide complete lines of safe, scientifically-tested, guaranteed products that promote health and wellness - naturally.

7 Dec 2009

Overview of the important research and treatments in ADHD

Worldwide longitudinal studies performed since the 1970s have clearly shown that ADHD persists into adulthood. These findings have stimulated researchers to develop the therapeutic approaches for adult patients, especially in European countries where scientific and clinical interest in ADHD has increased.

4 Dec 2009

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.

3 Dec 2009

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

MRI pioneer honored with MRC Millennium Medal

Sir Peter Mansfield, The University of Nottingham's Nobel Laureate for Physiology and Medicine, is to be recognised, once again, for his part in one of the most important breakthroughs in medical science.

2 Dec 2009